GlassScriptPhysician profile
Xiaohong Jiang
NPI 1063137263
$3,644.86
in general payments reported to CMS, 2019-2025
34 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 91% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $128 · 2023: $633 · 2024: $1,577 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496 · Long Term Medical Supply Or Device Loan: $798 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.47 |
| Long Term Medical Supply Or Device Loan | $797.60 |
| Education | $222.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $949.10 | 2023-2025 | |
| Daiichi Sankyo INC. | $333.64 | 2023-2025 | Enhertu, Vanflyta, Datroway |
| Astrazeneca Pharmaceuticals LP | $313.05 | 2023-2025 | Calquence, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $185.39 | 2023-2025 | Fruzaqla, Iclusig |
| Incyte Corporation | $180.47 | 2022-2024 | Pemazyre, Monjuvi, Jakafi |
| Janssen Biotech, INC. | $156.87 | 2024-2025 | Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $133.63 | 2023-2025 | Keytruda, Welireg |
| E.R. Squibb & Sons, L.L.C. | $123.35 | 2023-2025 | Opdivo, Krazati, Augtyro |
| Regeneron Healthcare Solutions, INC. | $117.53 | 2023-2024 | Libtayo |
| Glaxosmithkline, LLC. | $109.97 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Apellis Pharmaceuticals, INC. | $109.59 | 2022 | |
| Exelixis INC. | $94.28 | 2023-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $77.99 | 2023 | Imbruvica |
| Abbvie INC. | $62.87 | 2024 | |
| Beigene USA, INC. | $58.64 | 2024 | Brukinsa, Tevimbra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $55.96 | 2023-2024 | Padcev |
| Ethicon US, LLC | $52.26 | 2024-2025 | Echelon Flex, Enseal, Ethicon |
| Taiho Oncology, INC. | $51.73 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $51.54 | 2023-2024 | Givlaari |
| Alexion Pharmaceuticals, INC. | $49.64 | 2023-2024 | Ultomiris |
| Seagen INC. | $40.24 | 2023 | Tivdak |
| Caris Mpi, INC. | $37.25 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $33.51 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.00 | 2025 | |
| Amgen INC. | $29.45 | 2023 | Lumakras, Vectibix, Neulasta |
| Lilly USA, LLC | $28.21 | 2024 | Verzenio, Jaypirca |
| Pharmacosmos Therapeutics INC. | $27.72 | 2024 | Monoferric |
| Mirati Therapeutics, INC. | $25.76 | 2024 | Krazati |
| Morphosys, US INC. | $24.80 | 2023 | Monjuvi |
| Tersera Therapeutics LLC | $22.43 | 2025 | Zoladex |
| Azurity Pharmaceuticals, INC. | $21.67 | 2024 | Vivimusta |
| Adc Therapeutics America, INC. | $21.16 | 2024 | |
| Recordati_rare_diseases_inc. | $20.36 | 2023 | Sylvant |
| Eisai INC. | $14.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaohong Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.